U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
U.S. Justice Department Removes DHS Lawyer After Blunt Remarks in Minnesota Immigration Court 
Trump Administration Sued Over Suspension of Critical Hudson River Tunnel Funding 
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Sam Altman Criticizes ICE Enforcement as Corporate Leaders Call for De-Escalation 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash 
U.S. Imposes Visa Restrictions on Haiti Transitional Council Over Gang Allegations 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
The U.S. Food and Drug Administration has appointed Tracy Beth Høeg as the acting director of the Center for Drug Evaluation and Research (CDER), stepping in shortly after Richard Pazdur revealed he will retire only weeks into his tenure. The unexpected leadership shift comes at a critical time for the FDA, as the agency continues to navigate an evolving regulatory landscape, rising drug development demands, and growing scrutiny over internal decision-making processes.
Pazdur, a highly respected oncology expert known for modernizing cancer drug approvals, assumed the CDER leadership role on November 11. His move followed the resignation of former director George Tidmarsh, who stepped down amid serious concerns surrounding his personal conduct. Pazdur’s appointment was initially seen as a stabilizing choice, given his decades of experience and influence within the FDA’s Oncology Center of Excellence. However, his early retirement has prompted a rapid transition in leadership, increasing attention on the agency’s next steps.
The FDA’s selection of Tracy Beth Høeg signals a focus on continuity and expertise. Høeg brings extensive experience in public health, clinical research, and regulatory oversight, positioning her to guide CDER through ongoing priorities such as drug safety evaluations, accelerated approvals, and innovation in therapeutic development. Her leadership will be essential as the agency works to maintain public trust and ensure efficient, evidence-based drug review processes.
This shift also underscores broader challenges within the FDA, including leadership stability and the pressure to manage high-profile regulatory decisions. With drug manufacturers, healthcare providers, and patients closely monitoring these developments, Høeg’s role will be crucial in ensuring consistent communication, transparent review practices, and effective policy implementation.
As the FDA navigates this transition, stakeholders across the pharmaceutical and healthcare sectors will be watching how the agency balances regulatory rigor with the urgent need for safe, effective medical treatments. The appointment of Høeg marks a significant moment for CDER, shaping how the agency continues to respond to scientific, clinical, and industry advancements in the months ahead.
